<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.48.0">
<page number="1" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="0" size="10" family="Times" color="#231f20"/>
	<fontspec id="1" size="25" family="Times" color="#231f20"/>
	<fontspec id="2" size="14" family="Times" color="#231f20"/>
	<fontspec id="3" size="7" family="Times" color="#231f20"/>
	<fontspec id="4" size="22" family="Times" color="#231f20"/>
<image top="189" left="106" width="165" height="205" src="/export/freefileconvert/28709_bcb4c90b4197e4615785b5d89d352a843ea053a56053d02ed81ebcc1ea128523-1_1.png"/>
<text top="108" left="106" width="210" height="12" font="0">Archives of the Balkan Medical Union</text>
<text top="122" left="106" width="226" height="12" font="0">Copyright © 2019 Balkan Medical Union</text>
<text top="108" left="636" width="151" height="12" font="0">vol. 54, no. 2, pp. 219-221</text>
<text top="122" left="728" width="59" height="12" font="0">June 2019</text>
<text top="431" left="106" width="295" height="27" font="1">OXIDATIVE STRESS AND </text>
<text top="461" left="106" width="191" height="27" font="1">HEART FAILURE</text>
<text top="539" left="136" width="300" height="19" font="2">Oxidative stress is involved in the pathophysiol-</text>
<text top="558" left="106" width="333" height="19" font="2">ogy of many chronic diseases, including heart failure. </text>
<text top="577" left="106" width="329" height="19" font="2">Oxidative stress is an imbalance between the produc-</text>
<text top="596" left="106" width="329" height="19" font="2">tion of reactive oxygen species (ROS) and the antiox-</text>
<text top="615" left="106" width="334" height="19" font="2">idant defense. The overproduction of ROS can lead </text>
<text top="634" left="106" width="333" height="19" font="2">to cellular damage and eventually cellular death. This </text>
<text top="653" left="106" width="334" height="19" font="2">applies also in patients with chronic heart failure, </text>
<text top="672" left="106" width="334" height="19" font="2">who present a dramatic increase of oxidative stress </text>
<text top="691" left="106" width="329" height="19" font="2">associated with a pronounced decrease of the antioxi-</text>
<text top="710" left="106" width="329" height="19" font="2">dant defense mechanisms. The components of the an-</text>
<text top="729" left="106" width="334" height="19" font="2">tioxidant defense mechanism of myocardial cells are </text>
<text top="748" left="106" width="334" height="19" font="2">superoxide dismutase (SOD), catalase, nicotinamide </text>
<text top="767" left="106" width="333" height="19" font="2">adenine dinucleotide (NAD+), glutathione peroxidase </text>
<text top="786" left="106" width="334" height="19" font="2">(GPx), and glutathione (GSH). Experimental animal </text>
<text top="805" left="106" width="330" height="19" font="2">studies have demonstrated the decrease of the activi-</text>
<text top="824" left="106" width="334" height="19" font="2">ty of SOD, catalase and GPx in animal models with </text>
<text top="843" left="106" width="79" height="19" font="2">heart failure</text>
<text top="843" left="185" width="12" height="11" font="3">1,2</text>
<text top="843" left="197" width="243" height="19" font="2">. Furthermore, excessive ROS induce </text>
<text top="862" left="106" width="330" height="19" font="2">myocardial fibroblasts proliferation with cardiac re-</text>
<text top="880" left="106" width="335" height="19" font="2">modeling. The promising results of experimental </text>
<text top="899" left="106" width="329" height="19" font="2">studies in animals with heart failure led to the hy-</text>
<text top="918" left="106" width="330" height="19" font="2">pothesis that oxidative stress may be a therapeutic tar-</text>
<text top="937" left="106" width="333" height="19" font="2">get in patients with heart failure. Clinical trials have </text>
<text top="956" left="106" width="329" height="19" font="2">studied the effects of antioxidant treatments in hu-</text>
<text top="975" left="106" width="333" height="19" font="2">mans with heart failure. Treatment of oxidative stress </text>
<text top="994" left="106" width="333" height="19" font="2">can have different approaches: inhibition of oxidative </text>
<text top="1013" left="106" width="333" height="19" font="2">stress producers, increase of endogenous antioxidant </text>
<text top="1032" left="106" width="329" height="19" font="2">capacity, and increase of antioxidant capacity by ad-</text>
<text top="1051" left="106" width="329" height="19" font="2">ministration of exogenous antioxidants, such as vita-</text>
<text top="1070" left="106" width="333" height="19" font="2">min C, vitamin A, vitamin E, folic acid. Inhibition of </text>
<text top="431" left="457" width="312" height="27" font="1">LE STRESS OXYDATIF ET </text>
<text top="461" left="457" width="269" height="27" font="1">L’INSUFFISANCE CAR-</text>
<text top="491" left="457" width="94" height="27" font="1">DIAQUE</text>
<text top="539" left="487" width="300" height="19" font="2">Le stress oxydatif est impliqué dans la physio-</text>
<text top="558" left="457" width="335" height="19" font="2">pathologie de nombreuses maladies chroniques, y </text>
<text top="577" left="457" width="334" height="19" font="2">compris l’insuffisance cardiaque. Le stress oxydatif </text>
<text top="596" left="457" width="329" height="19" font="2">est un déséquilibre entre la production d’espèces ré-</text>
<text top="615" left="457" width="333" height="19" font="2">actives de l’oxygène (ROS) et la défense antioxydante. </text>
<text top="634" left="457" width="329" height="19" font="2">La surproduction de ROS peut entraîner des dom-</text>
<text top="653" left="457" width="333" height="19" font="2">mages cellulaires et éventuellement la mort cellulaire. </text>
<text top="672" left="457" width="329" height="19" font="2">Ceci s’applique également aux patients souffrant d’in-</text>
<text top="691" left="457" width="334" height="19" font="2">suffisance cardiaque chronique, qui présentent une </text>
<text top="710" left="457" width="333" height="19" font="2">augmentation dramatique du stress oxydatif associée </text>
<text top="729" left="457" width="329" height="19" font="2">à une diminution prononcée des mécanismes de dé-</text>
<text top="748" left="457" width="334" height="19" font="2">fense anti-oxydants. Les composants du mécanisme </text>
<text top="767" left="457" width="335" height="19" font="2">de défense anti-oxydant des cellules du myocarde </text>
<text top="786" left="457" width="334" height="19" font="2">sont la superoxyde dismutase (SOD), la catalase, le </text>
<text top="805" left="457" width="329" height="19" font="2">nicotinamide adénine dinucléotide (NAD +), la glu-</text>
<text top="824" left="457" width="333" height="19" font="2">tathion-péroxydase  (GPx)  et  la  glutathion  (GSH). </text>
<text top="843" left="457" width="335" height="19" font="2">Des études expérimentales sur des animaux ont </text>
<text top="862" left="457" width="333" height="19" font="2">démontré la diminution de l’activité de la SOD, de </text>
<text top="880" left="457" width="329" height="19" font="2">la catalase et du GPx dans des modèles animaux at-</text>
<text top="899" left="457" width="196" height="19" font="2">teints d’insuffisance cardiaque</text>
<text top="900" left="652" width="12" height="11" font="3">1,2</text>
<text top="899" left="664" width="127" height="19" font="2">. De plus, des ROS </text>
<text top="918" left="457" width="333" height="19" font="2">excessives induisent une prolifération des fibroblastes </text>
<text top="937" left="457" width="329" height="19" font="2">du myocarde avec un remodelage cardiaque. Les ré-</text>
<text top="956" left="457" width="335" height="19" font="2">sultats prometteurs d’études expérimentales chez </text>
<text top="975" left="457" width="334" height="19" font="2">des animaux souffrant d’insuffisance cardiaque ont </text>
<text top="994" left="457" width="333" height="19" font="2">conduit à l’hypothèse selon laquelle le stress oxydatif </text>
<text top="1013" left="457" width="334" height="19" font="2">pourrait constituer une cible thérapeutique chez les </text>
<text top="1032" left="457" width="334" height="19" font="2">patients insuffisants cardiaques. Des essais cliniques </text>
<text top="1051" left="457" width="335" height="19" font="2">ont étudié les effets des traitements antioxydants </text>
<text top="1070" left="457" width="335" height="19" font="2">chez l’homme atteint d’insuffisance cardiaque. Le </text>
<text top="190" left="679" width="108" height="24" font="4">EDITORIAL</text>
<text top="227" left="543" width="243" height="12" font="0">https://doi.org/10.31688/ABMU.2019.54.2.219</text>
<text top="298" left="284" width="135" height="17" font="2"> Camelia DIACONU</text>
<text top="297" left="418" width="3" height="10" font="3"> </text>
<text top="298" left="429" width="5" height="17" font="2"> </text>
<text top="316" left="284" width="433" height="17" font="2">International Secretary General of the Balkan Medical Union</text>
<text top="335" left="284" width="309" height="17" font="2">President of the Romanian National Section</text>
<text top="362" left="284" width="462" height="17" font="2">Secrétaire Général International de l’Union Médicale Balkanique</text>
<text top="381" left="284" width="327" height="17" font="2">Présidente de la Section Nationale Roumaine</text>
<text top="1149" left="144" width="255" height="13" font="0"> Correspondence address:   Camelia DIACONU</text>
<text top="1167" left="302" width="193" height="13" font="0">email drcameliadiaconu@gmail.com</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="5" size="11" family="Times" color="#231f20"/>
<text top="91" left="106" width="109" height="14" font="5">Camelia DIACONU</text>
<text top="1182" left="106" width="143" height="14" font="5">220  /  vol. 54, no. 2</text>
<text top="126" left="106" width="333" height="19" font="2">xanthine oxidase by the administration of allopurinol </text>
<text top="145" left="106" width="333" height="19" font="2">or oxypurinol in patients with chronic heart failure </text>
<text top="164" left="106" width="186" height="19" font="2">is the most studied treatment </text>
<text top="164" left="292" width="11" height="11" font="3">3,4</text>
<text top="164" left="303" width="136" height="19" font="2">. Different trials have </text>
<text top="182" left="106" width="335" height="19" font="2">demonstrated that treatment with allopurinol or </text>
<text top="201" left="106" width="329" height="19" font="2">oxypurinol (inhibitors of oxidative stress) had ben-</text>
<text top="220" left="106" width="335" height="19" font="2">eficial effects on myocardial function, endothelial </text>
<text top="239" left="106" width="333" height="19" font="2">dysfunction, and led to the decreased levels of serum </text>
<text top="257" left="106" width="329" height="19" font="2">natriuretic peptides and improved left ventricle ejec-</text>
<text top="276" left="106" width="82" height="19" font="2">tion fraction</text>
<text top="277" left="189" width="12" height="11" font="3">3,4</text>
<text top="276" left="200" width="240" height="19" font="2">.  Other trials failed to demonstrate </text>
<text top="295" left="106" width="225" height="19" font="2">the beneficial effects of oxypurinol</text>
<text top="296" left="332" width="5" height="11" font="3">5</text>
<text top="295" left="337" width="103" height="19" font="2">. Other clinical </text>
<text top="314" left="106" width="329" height="19" font="2">studies focused on the effects of increasing the an-</text>
<text top="332" left="106" width="333" height="19" font="2">tioxidant capacity in patients with heart failure, by </text>
<text top="351" left="106" width="334" height="19" font="2">administration of vitamin A, vitamin C, vitamin E </text>
<text top="370" left="106" width="333" height="19" font="2">or folic acid. Despite the initial enthusiasm regarding </text>
<text top="389" left="106" width="329" height="19" font="2">the effects of these antioxidants, a recent meta-analy-</text>
<text top="407" left="106" width="329" height="19" font="2">sis of 50 randomized trials on their cardiovascular ef-</text>
<text top="426" left="106" width="330" height="19" font="2">fects, including almost 300,000 patients, has demon-</text>
<text top="445" left="106" width="333" height="19" font="2">strated that supplementation with vitamins and other </text>
<text top="464" left="106" width="333" height="19" font="2">antioxidants failed to demonstrate a decrease of the </text>
<text top="482" left="106" width="334" height="19" font="2">cardiovascular risk. The third therapeutic approach, </text>
<text top="501" left="106" width="334" height="19" font="2">increase of endogenous antioxidant capacity, may be </text>
<text top="520" left="106" width="333" height="19" font="2">achieved by supplementation of cellular antioxidants </text>
<text top="539" left="106" width="111" height="19" font="2">GSH and NAD+</text>
<text top="539" left="218" width="5" height="11" font="3">6</text>
<text top="539" left="223" width="218" height="19" font="2">. This strategy has been studied </text>
<text top="557" left="106" width="334" height="19" font="2">only in a few trials, but their results until now seem </text>
<text top="576" left="106" width="333" height="19" font="2">to be promising. Supplementation with NAC, which </text>
<text top="595" left="106" width="333" height="19" font="2">is a precursor of GSH, in patients with chronic heart </text>
<text top="614" left="106" width="329" height="19" font="2">failure can be a potential approach in order to de-</text>
<text top="632" left="106" width="334" height="19" font="2">crease the oxidative stress secondary to myocardial </text>
<text top="651" left="106" width="37" height="19" font="2">injury</text>
<text top="652" left="144" width="5" height="11" font="3">6</text>
<text top="651" left="149" width="8" height="19" font="2">. </text>
<text top="670" left="136" width="304" height="19" font="2">The improvement of the expression and activity </text>
<text top="689" left="106" width="333" height="19" font="2">of the gamma-glutamyl cycle and NAD+ producers is </text>
<text top="707" left="106" width="329" height="19" font="2">another option to increase the endogenous produc-</text>
<text top="726" left="106" width="333" height="19" font="2">tion of antioxidants in heart failure. Some studies </text>
<text top="745" left="106" width="333" height="19" font="2">have  demonstrated  that  a  few  components  of  the </text>
<text top="764" left="106" width="330" height="19" font="2">gamma-glutamyl cycle (gamma-glutamyl-cysteine syn-</text>
<text top="782" left="106" width="334" height="19" font="2">thetase, GPx, OPLAH) are correlated with the risk </text>
<text top="801" left="106" width="225" height="19" font="2">of heart failure and its progression</text>
<text top="802" left="330" width="5" height="11" font="3">7</text>
<text top="801" left="335" width="106" height="19" font="2">. Therefore, the </text>
<text top="820" left="106" width="329" height="19" font="2">overexpression of these enzymes may have cardiopro-</text>
<text top="839" left="106" width="334" height="19" font="2">tective effects. OPLAH is a cytoplasmic enzyme of </text>
<text top="857" left="106" width="330" height="19" font="2">the GSH cycle, with a central function in the gam-</text>
<text top="876" left="106" width="330" height="19" font="2">ma-glutamyl cycle and also with an important anti-</text>
<text top="895" left="106" width="333" height="19" font="2">oxidant function; its expression is decreased in heart </text>
<text top="914" left="106" width="334" height="19" font="2">failure. Therefore, the stimulation of the expression </text>
<text top="932" left="106" width="333" height="19" font="2">and activity of OPLAH in patients with heart failure </text>
<text top="951" left="106" width="298" height="19" font="2">may play an important role for their prognosis. </text>
<text top="970" left="136" width="300" height="19" font="2">In conclusion, oxidative stress may play an im-</text>
<text top="989" left="106" width="334" height="19" font="2">portant role in patients with chronic heart failure. </text>
<text top="1007" left="106" width="329" height="19" font="2">Experimental studies have demonstrated the benefi-</text>
<text top="1026" left="106" width="333" height="19" font="2">cial effects of therapies addressing the oxidative stress </text>
<text top="1045" left="106" width="334" height="19" font="2">in animals. However, until now, these effects have </text>
<text top="1064" left="106" width="329" height="19" font="2">not been fully demonstrated by clinical trials in hu-</text>
<text top="1082" left="106" width="329" height="19" font="2">mans. Further antioxidant strategies must be studied.</text>
<text top="126" left="457" width="333" height="19" font="2">traitement du stress oxydatif peut avoir différentes </text>
<text top="145" left="457" width="330" height="19" font="2">approches : inhibition des producteurs de stress oxy-</text>
<text top="164" left="457" width="329" height="19" font="2">datif, augmentation de la capacité antioxydante en-</text>
<text top="182" left="457" width="333" height="19" font="2">dogène et augmentation de la capacité antioxydante </text>
<text top="201" left="457" width="335" height="19" font="2">par l’administration d’antioxydants exogènes, tels </text>
<text top="220" left="457" width="333" height="19" font="2">que la vitamine C, la vitamine A, la vitamine E et </text>
<text top="239" left="457" width="333" height="19" font="2">l’acide folique. L’inhibition de la xanthine oxydase </text>
<text top="257" left="457" width="334" height="19" font="2">par l’administration d’allopurinol ou d’oxypurinol </text>
<text top="276" left="457" width="334" height="19" font="2">chez les patients insuffisants cardiaques chroniques </text>
<text top="295" left="457" width="201" height="19" font="2">est le traitement le plus étudié</text>
<text top="296" left="659" width="12" height="11" font="3">3,4</text>
<text top="295" left="670" width="121" height="19" font="2">. Différents essais </text>
<text top="314" left="457" width="334" height="19" font="2">ont démontré que le traitement par l’allopurinol ou </text>
<text top="332" left="457" width="334" height="19" font="2">l’oxypurinol (inhibiteurs du stress oxydant) avait des </text>
<text top="351" left="457" width="333" height="19" font="2">effets bénéfiques sur la fonction myocardique, un </text>
<text top="370" left="457" width="335" height="19" font="2">dysfonctionnement endothélial et une diminution </text>
<text top="389" left="457" width="334" height="19" font="2">des niveaux de peptides natriurétiques sériques et </text>
<text top="407" left="457" width="334" height="19" font="2">une fraction améliorée de l’éjection du ventricule </text>
<text top="426" left="457" width="43" height="19" font="2">gauche</text>
<text top="427" left="501" width="12" height="11" font="3">3,4</text>
<text top="426" left="513" width="274" height="19" font="2">. D’autres essais n’ont pas démontré les ef-</text>
<text top="445" left="457" width="210" height="19" font="2">fets  bénéfiques  de  l’oxypurinol</text>
<text top="446" left="668" width="5" height="11" font="3">5</text>
<text top="445" left="672" width="120" height="19" font="2">. D’autres études </text>
<text top="464" left="457" width="334" height="19" font="2">cliniques ont porté sur les effets de l’augmentation </text>
<text top="482" left="457" width="329" height="19" font="2">de la capacité antioxydante chez les patients insuf-</text>
<text top="501" left="457" width="334" height="19" font="2">fisants cardiaques, par l’administration de vitamine </text>
<text top="520" left="457" width="333" height="19" font="2">A, de vitamine C, de vitamine E ou d’acide folique. </text>
<text top="539" left="457" width="335" height="19" font="2">Malgré l’enthousiasme initial suscité par les effets </text>
<text top="557" left="457" width="334" height="19" font="2">de ces antioxydants, une méta-analyse récente de 50 </text>
<text top="576" left="457" width="334" height="19" font="2">essais randomisés sur leurs effets cardiovasculaires, </text>
<text top="595" left="457" width="333" height="19" font="2">incluant près de 300 000 patients, a démontré qu’une </text>
<text top="614" left="457" width="333" height="19" font="2">supplémentation en vitamines et autres antioxydants </text>
<text top="632" left="457" width="335" height="19" font="2">ne permettait pas de démontrer une diminution </text>
<text top="651" left="457" width="335" height="19" font="2">du risque cardiovasculaire. La troisième approche </text>
<text top="670" left="457" width="329" height="19" font="2">thérapeutique, à savoir l’augmentation de la capaci-</text>
<text top="689" left="457" width="334" height="19" font="2">té antioxydante endogène, peut être obtenue par la </text>
<text top="707" left="457" width="335" height="19" font="2">supplémentation en antioxydants cellulaires GSH </text>
<text top="726" left="457" width="59" height="19" font="2">et NAD+</text>
<text top="727" left="517" width="5" height="11" font="3">6</text>
<text top="726" left="522" width="270" height="19" font="2">. Cette stratégie n’a été étudiée que dans </text>
<text top="745" left="457" width="333" height="19" font="2">quelques essais, mais leurs résultats semblent jusqu’à </text>
<text top="764" left="457" width="334" height="19" font="2">présent prometteurs. La supplémentation en NAC, </text>
<text top="782" left="457" width="333" height="19" font="2">précurseur du GSH, chez les patients insuffisants </text>
<text top="801" left="457" width="334" height="19" font="2">cardiaques chroniques peut constituer une approche </text>
<text top="820" left="457" width="334" height="19" font="2">potentielle pour réduire le stress oxydatif lié à une </text>
<text top="839" left="457" width="121" height="19" font="2">lésion du myocarde</text>
<text top="839" left="578" width="5" height="11" font="3">6</text>
<text top="839" left="583" width="4" height="19" font="2">.</text>
<text top="857" left="487" width="304" height="19" font="2">L’amélioration de l’expression et de l’activité du </text>
<text top="876" left="457" width="334" height="19" font="2">cycle gamma-glutamyl et des producteurs de NAD + </text>
<text top="895" left="457" width="329" height="19" font="2">est une autre option permettant d’accroître la produc-</text>
<text top="914" left="457" width="329" height="19" font="2">tion endogène d’antioxydants dans l’insuffisance car-</text>
<text top="932" left="457" width="334" height="19" font="2">diaque. Certaines études ont démontré que quelques </text>
<text top="951" left="457" width="330" height="19" font="2">composants du cycle gamma-glutamyl (gamma-glu-</text>
<text top="970" left="457" width="333" height="19" font="2">tamyl-cystéine synthétase, GPx, OPLAH) sont corrélés </text>
<text top="989" left="457" width="322" height="19" font="2">au risque d’insuffisance cardiaque et à sa progression</text>
<text top="989" left="779" width="5" height="11" font="3">7</text>
<text top="989" left="783" width="8" height="19" font="2">. </text>
<text top="1007" left="457" width="333" height="19" font="2">Par conséquent, la surexpression de ces enzymes peut </text>
<text top="1026" left="457" width="329" height="19" font="2">avoir des effets cardioprotecteurs. OPLAH est une en-</text>
<text top="1045" left="457" width="334" height="19" font="2">zyme cytoplasmique du cycle GSH, qui joue un rôle </text>
<text top="1064" left="457" width="334" height="19" font="2">central dans le cycle gamma-glutamyl et qui possède </text>
<text top="1082" left="457" width="333" height="19" font="2">également une fonction antioxydante importante. Son </text>
<text top="1101" left="457" width="333" height="19" font="2">expression est diminuée dans l’insuffisance cardiaque. </text>
<text top="1120" left="457" width="334" height="19" font="2">Par conséquent, la stimulation de l’expression et de </text>
<text top="1139" left="457" width="334" height="19" font="2">l’activité de l’OPLAH chez les patients insuffisants </text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="6" size="14" family="Times" color="#231f20"/>
	<fontspec id="7" size="16" family="Times" color="#231f20"/>
	<fontspec id="8" size="11" family="Times" color="#231f20"/>
<text top="91" left="552" width="235" height="14" font="5">Archives of the Balkan Medical Union</text>
<text top="1182" left="661" width="42" height="14" font="5">June </text>
<text top="1182" left="693" width="94" height="14" font="5">2019 / 221</text>
<text top="126" left="458" width="333" height="19" font="2">cardiaques peut jouer un rôle important dans leur </text>
<text top="145" left="458" width="62" height="19" font="2">pronostic.</text>
<text top="164" left="487" width="304" height="19" font="2">En conclusion, le stress oxydatif peut jouer un </text>
<text top="182" left="458" width="330" height="19" font="2">rôle important chez les patients insuffisants car-</text>
<text top="201" left="458" width="334" height="19" font="2">diaques chroniques. Des études expérimentales ont </text>
<text top="220" left="458" width="333" height="19" font="2">démontré les effets bénéfiques des thérapies destinées </text>
<text top="239" left="458" width="333" height="19" font="2">à lutter contre le stress oxydatif chez les animaux. </text>
<text top="257" left="458" width="334" height="19" font="2">Cependant, jusqu’à présent, ces effets n’ont pas été </text>
<text top="276" left="458" width="333" height="19" font="2">complètement démontrés par les essais cliniques chez </text>
<text top="295" left="458" width="329" height="19" font="2">l’homme. Des stratégies antioxydantes supplémen-</text>
<text top="314" left="458" width="172" height="19" font="2">taires doivent être étudiées.</text>
<text top="356" left="106" width="157" height="16" font="6"><i><b>„No conflict of interest.“</b></i></text>
<text top="412" left="106" width="12" height="18" font="7">R</text>
<text top="416" left="118" width="71" height="13" font="0">EFERENCES</text>
<text top="447" left="106" width="684" height="15" font="5">1. Khaper N, Singal PK. Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in </text>
<text top="463" left="128" width="208" height="15" font="5">rats. <i>J Am Coll Cardiol</i> 1997;29:856–861.</text>
<text top="478" left="106" width="684" height="15" font="5">2. Khaper N, Kaur K, Li T, Farahmand F, Singal PK. Antioxidant enzyme gene expression in congestive heart failure following </text>
<text top="494" left="128" width="280" height="15" font="5">mycardial infarction. <i>Mol Cell</i> <i>Biochem </i>2003;251:9–15.</text>
<text top="510" left="106" width="680" height="15" font="5">3. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. <i>J Am Coll Cardiol</i> 2008;51:2301-</text>
<text top="526" left="128" width="29" height="15" font="5">2309.</text>
<text top="541" left="106" width="684" height="15" font="5">4. Farquharson CAJ, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. </text>
<text top="557" left="128" width="152" height="15" font="8"><i>Circulation</i> 2002;106:221-226.</text>
<text top="573" left="106" width="680" height="15" font="5">5. Freudenberger RS, Schwarz RP, Brown J, et al. Rationale, design and organization of an efficacy and safety study of oxypurinol add-</text>
<text top="589" left="128" width="662" height="15" font="5">ed to standard therapy in patients with NYHA class III-IV congestive heart failure. <i>Expert Opin Investig Drugs</i> 2004;13:1509-1516. </text>
<text top="604" left="106" width="683" height="15" font="5">6. Mehra A, Shotan A, Ostrzega E, Hsueh W, Vasquez-Johnson J, Elkayam U. Potentiation of isosorbide dinitrate effects with </text>
<text top="620" left="128" width="447" height="15" font="5">N-acetylcysteine in patients with chronic heart failure. <i>Circulation</i> 1994;89:2595-2600.</text>
<text top="636" left="106" width="680" height="15" font="5">7. Schupp N, Schmid U, Heidland A, Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via up-</text>
<text top="652" left="128" width="354" height="15" font="5">regulation of glutathione synthesis. <i>Atherosclerosis</i> 2008;199:278-287.</text>
</page>
</pdf2xml>
